BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17657220)

  • 1. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia.
    Raaijmakers MH
    Leukemia; 2007 Oct; 21(10):2094-102. PubMed ID: 17657220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug.
    Chapuy B; Panse M; Radunski U; Koch R; Wenzel D; Inagaki N; Haase D; Truemper L; Wulf GG
    Haematologica; 2009 Nov; 94(11):1528-36. PubMed ID: 19880777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34+ hematopoietic progenitor cells.
    Porro A; Iraci N; Soverini S; Diolaiti D; Gherardi S; Terragna C; Durante S; Valli E; Kalebic T; Bernardoni R; Perrod C; Haber M; Norris MD; Baccarani M; Martinelli G; Perini G
    Mol Cancer Res; 2011 Aug; 9(8):1054-66. PubMed ID: 21693596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
    Svensson E; Vidovic K; Lassen C; Richter J; Olofsson T; Fioretos T; Gullberg U
    Leukemia; 2007 Dec; 21(12):2485-94. PubMed ID: 17728783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
    Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
    Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
    Turrini E; Haenisch S; Laechelt S; Diewock T; Bruhn O; Cascorbi I
    Pharmacogenet Genomics; 2012 Mar; 22(3):198-205. PubMed ID: 22241070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
    Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
    Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of stem cell markers in multidrug resistance mediated by ABC transporters.
    Tiwari AK; An X; Chen ZS
    Leuk Res; 2010 Jun; 34(6):696-7. PubMed ID: 20061021
    [No Abstract]   [Full Text] [Related]  

  • 10. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance.
    de Jonge-Peeters SD; Kuipers F; de Vries EG; Vellenga E
    Crit Rev Oncol Hematol; 2007 Jun; 62(3):214-26. PubMed ID: 17368038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways.
    Dharmapuri G; Doneti R; Philip GH; Kalle AM
    Leuk Res; 2015 Jul; 39(7):696-701. PubMed ID: 25916699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia.
    Zong Y; Zhou S; Sorrentino BP
    Leukemia; 2005 Sep; 19(9):1590-6. PubMed ID: 16001089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
    Casetti L; Martin-Lannerée S; Najjar I; Plo I; Augé S; Roy L; Chomel JC; Lauret E; Turhan AG; Dusanter-Fourt I
    Cancer Res; 2013 Apr; 73(7):2052-8. PubMed ID: 23400594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
    Ho MM; Hogge DE; Ling V
    Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABC transporters as phenotypic markers and functional regulators of stem cells.
    Bunting KD
    Stem Cells; 2002; 20(1):11-20. PubMed ID: 11796918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib.
    Glodkowska-Mrowka E; Mrowka P; Basak GW; Niesiobedzka-Krezel J; Seferynska I; Wlodarski PK; Jakobisiak M; Stoklosa T
    Exp Hematol; 2014 Jun; 42(6):439-47. PubMed ID: 24667683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
    Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
    Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
    Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
    Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
    O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.